Facilitating access to Coartem® Dispersible for the treatment of acute uncomplicated malaria in children

Children under 5 bear 67% of the burden of global malaria mortality, Coartem Dispersible is a treatment specifically designed to meet children’s needs.  

Launching Coartem Dispersible in 25 countries 

Over 25 countries participated in launch events forCoartem Dispersible in Southern, West, and East Africa, organized by Novartis and MMV. 

Patient-friendly packaging and healthcare worker training materials were developed (in both French and English).  

Preparing the introduction of Coartem Dispersible in six countries 

MMV supported a multi-country analysis to understand the barriers to acceptance of WHO-recommended child-friendly treatments for malaria. This study was conducted in six francophone countries in Africa: Benin, Burkina Faso, Cameroon, Gabon, Mali, and Senegal.  

Recommendations from this study were shared with the World Health Organization’s ‘Better Medicines for Children’ programme. Read the summary of findings. 


  • Past and current partners:

    Novartis, Dalberg Consulting, Ministry of Health Malawi, National Malaria Control Programmes, Pharmacy & Poisons Board of Malawi, PSI, WHO.